{"id":481672,"date":"2021-04-26T09:04:39","date_gmt":"2021-04-26T13:04:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/"},"modified":"2021-04-26T09:04:39","modified_gmt":"2021-04-26T13:04:39","slug":"turning-point-therapeutics-to-host-first-quarter-2021-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/","title":{"rendered":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call"},"content":{"rendered":"
\n

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on May 5. The company will host a conference call at 2:00 p.m. PT\/5:00 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session.<\/p>\n

The update will be accessible via audio webcast through the “Investors” section of www.tptherapeutics.com<\/a> or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID\u00a07397513. A replay will be available through the “Investors” section of www.tptherapeutics.com<\/a>.<\/p>\n

\n About Turning Point Therapeutics Inc.<\/strong>
\n
Turning Point Therapeutics\u00a0is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company\u2019s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1\/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-na\u00efve and pre-treated patients. The company\u2019s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1\/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1\/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point\u2019s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>
\n
Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cplans\u201d, \u201cwill\u201d, \u201cbelieves,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cgoal,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics\u2019 current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics\u2019 business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point\u2019s business and the other risks described in Turning Point Therapeutics\u2019 filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n

Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com<\/a>
858-342-8272<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on May 5. The company will host a conference call at 2:00 p.m. PT\/5:00 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the “Investors” section of www.tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID\u00a07397513. A replay will be available through … <\/p>\n

Continue reading “Turning Point Therapeutics to Host First Quarter 2021 Conference Call”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-481672","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTurning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Turning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on May 5. The company will host a conference call at 2:00 p.m. PT\/5:00 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the “Investors” section of www.tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID\u00a07397513. A replay will be available through … Continue reading "Turning Point Therapeutics to Host First Quarter 2021 Conference Call"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-26T13:04:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Turning Point Therapeutics to Host First Quarter 2021 Conference Call\",\"datePublished\":\"2021-04-26T13:04:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/\"},\"wordCount\":600,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/\",\"name\":\"Turning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=\",\"datePublished\":\"2021-04-26T13:04:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Turning Point Therapeutics to Host First Quarter 2021 Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk","og_description":"SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on May 5. The company will host a conference call at 2:00 p.m. PT\/5:00 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session. The update will be accessible via audio webcast through the “Investors” section of www.tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID\u00a07397513. A replay will be available through … Continue reading \"Turning Point Therapeutics to Host First Quarter 2021 Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-26T13:04:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call","datePublished":"2021-04-26T13:04:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/"},"wordCount":600,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/","name":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=","datePublished":"2021-04-26T13:04:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMzA4OCM0MTM3NDI0IzIxNzcyMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-to-host-first-quarter-2021-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Turning Point Therapeutics to Host First Quarter 2021 Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/481672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=481672"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/481672\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=481672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=481672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=481672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}